Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.08)
# 523
Out of 5,055 analysts
145
Total ratings
51.54%
Success rate
12.07%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $5.93 | +321.59% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $83.63 | +139.16% | 1 | Nov 6, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $85 → $95 | $71.45 | +32.96% | 6 | Nov 5, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.31 | +1,198.70% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $66.39 | +65.69% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $96.50 | +39.90% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.35 | +325.53% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $70.80 | -8.19% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $41.01 | +82.88% | 5 | Sep 8, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Overweight | n/a | $17.44 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $23.27 | +7.46% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.05 | +162.30% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $11.37 | +119.88% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $5.21 | +15.27% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $204.40 | +36.99% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $9.92 | +404.03% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $3.25 | +515.38% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $206.16 | +4.29% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.41 | +107.47% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $29.28 | +583.06% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.08 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.21 | +265.41% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.79 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.24 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $42.67 | +110.92% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.68 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $193.22 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $41.26 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.27 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.71 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $90.00 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.64 | +2,243.02% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $40.76 | +59.47% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $9.25 | -45.95% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $2.58 | +326.36% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $144.86 | -10.26% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $693.50 | +9.59% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $18.52 | -19.01% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $8.55 | +543.27% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.09 | +1,335.41% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.25 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $11.51 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $529.21 | -52.76% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $104.15 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $71.55 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.94 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $29.88 | -26.37% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.37 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.73 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $232.36 | -59.12% | 1 | Aug 17, 2017 |
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $5.93
Upside: +321.59%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $83.63
Upside: +139.16%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $85 → $95
Current: $71.45
Upside: +32.96%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.31
Upside: +1,198.70%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $66.39
Upside: +65.69%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $96.50
Upside: +39.90%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.35
Upside: +325.53%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $70.80
Upside: -8.19%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $41.01
Upside: +82.88%
Denali Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.44
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $23.27
Upside: +7.46%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.05
Upside: +162.30%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $11.37
Upside: +119.88%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.21
Upside: +15.27%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $204.40
Upside: +36.99%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $9.92
Upside: +404.03%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $3.25
Upside: +515.38%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $206.16
Upside: +4.29%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.41
Upside: +107.47%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $29.28
Upside: +583.06%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.08
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.21
Upside: +265.41%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.79
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.24
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $42.67
Upside: +110.92%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.68
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $193.22
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $41.26
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.71
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $90.00
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.64
Upside: +2,243.02%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $40.76
Upside: +59.47%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $9.25
Upside: -45.95%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.58
Upside: +326.36%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $144.86
Upside: -10.26%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $693.50
Upside: +9.59%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $18.52
Upside: -19.01%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $8.55
Upside: +543.27%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.09
Upside: +1,335.41%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.25
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $11.51
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $529.21
Upside: -52.76%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $104.15
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $71.55
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.94
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $29.88
Upside: -26.37%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $17.37
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $54.73
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $232.36
Upside: -59.12%